Cardinal Health Inc.

source: coverage-next-full | ticker: CAH | step: "01" | created: 2026-05-29

Step 01 — Business Overview: Cardinal Health Inc. (CAH)

Company Snapshot

Cardinal Health, Inc. (NYSE: CAH) is a global, integrated healthcare services and products company headquartered in Dublin, Ohio. With over $220 billion in annual revenue, it is one of the largest companies in the United States by top-line sales, though net income margins are razor-thin due to the low-margin nature of pharmaceutical distribution.

The company serves as a critical intermediary in the US healthcare supply chain — connecting pharmaceutical manufacturers with the pharmacies, hospitals, health systems, and specialty care providers that ultimately dispense drugs and medical products to patients.

CEO: Jason Hollar

Jason Hollar became Chief Executive Officer in August 2022, having previously served as Chief Financial Officer. He succeeded Mike Kaufmann. Hollar's tenure has been defined by:

• Managing the opioid settlement ($6.4B commitment) without financial distress
• Executing a Medical segment operational turnaround (margin recovery from negative territory in FY2022–2023)
• Accelerating the share repurchase program
• Evaluating strategic alternatives for nuclear pharmacy and specialty assets

Two Reportable Segments

1. Pharmaceutical and Specialty Solutions

The dominant revenue driver, generating approximately $210–220B in annual revenue. Cardinal Health is the third-largest pharmaceutical distributor in the US, behind McKesson and Cencora.

Core distribution business:

• Distributes branded and generic pharmaceuticals from 300+ manufacturers to approximately 29,000 pharmacy customer locations
• Serves retail pharmacies (CVS, Walgreens, independent pharmacies), mail-order pharmacies, hospitals, and health systems
• Revenue driven primarily by branded drug price inflation (pass-through) and generic volume

Specialty Solutions:

• Serves specialty physicians (oncologists, rheumatologists, neurologists) and specialty pharmacies
• Distributes high-cost specialty drugs (biologics, oncology agents, immunology drugs)
• Provides third-party logistics (3PL) services for specialty manufacturers
• Growing component of the segment — specialty drugs carry slightly better margins than broad commodity distribution

Nuclear & Precision Health Solutions:

• Operates the largest commercial nuclear pharmacy network in the US (~170 sites)
• Compounds and delivers radiopharmaceuticals for diagnostics (PET scans, SPECT scans) and targeted radionuclide therapy
• Unique asset with higher barriers to entry, better margins, and growing demand driven by Pluvicto-type therapies
• Sometimes discussed as a separate strategic asset

2. Global Medical Products and Distribution (GMPD / Medical Segment)

Approximately $15–16B annual revenue with operating margins targeting 2–3%+ range.

Distribution:

• Distributes branded and Cardinal Health-owned medical products to hospitals, surgery centers, laboratories
• Products include surgical supplies, PPE, exam gloves, procedure trays, lab consumables

Manufacturing:

• Manufactures Cardinal Health brand products (Presource procedure kits, surgical drapes/gowns, exam gloves, wound care)
• Manufacturing operations in the US, Ireland, Mexico, and Asia

Turnaround context:

• Medical segment suffered significant margin pressure in FY2022–FY2023 due to elevated raw material costs (exam gloves, resins), supply chain disruptions, and unfavorable long-term contracts
• Management executed cost reduction program, SKU rationalization, and renegotiated contracts
• Segment returned to positive operating income in FY2024; management targeting mid-single-digit margins over medium term

Revenue Scale and Mix

How CAH Makes Money

Cardinal Health's economics are fundamentally different from most companies. Despite $220B+ in revenue, GAAP operating income is typically $1.5–2.5B. The real profitability measure is non-GAAP adjusted operating earnings and free cash flow.

Key earning mechanisms:

1. Buy-side leverage: Negotiating manufacturer rebates, allowances, and distribution fees
2. Generic sourcing scale: Red Oak Sourcing LLC (50/50 JV with CVS Health) — largest generic drug sourcing entity in the US
3. Sell-side fees: Distribution service agreements (DSAs) with pharmacy customers
4. Working capital float: Hold inventory briefly; pay manufacturers 30–45 days after receipt; collect from pharmacies 7–15 days — positive working capital cycle generates float

Red Oak Sourcing JV

A critical competitive asset: Cardinal Health's 50/50 joint venture with CVS Health for generic drug purchasing. Red Oak is the largest generic drug purchasing organization in the US, giving CAH substantial buy-side leverage on generic sourcing costs. This JV is a structural moat that is not easily replicated.

Divestiture History (2020–2025)

Employees and Operations

• ~44,000 employees globally
• 25+ pharmaceutical distribution centers across the US
• ~170 nuclear pharmacy compounding/delivery sites
• Manufacturing facilities in US, Ireland, Mexico, Malaysia, Puerto Rico

Investment Characteristics

Cardinal Health presents as a low-growth, high-cash-return, defensive healthcare holding:

• Revenue grows with pharmaceutical price inflation + volume (GDP+ nominal)
• Earnings growth primarily from EPS expansion via buybacks and Medical segment margin recovery
• Highly predictable cash flows (essential healthcare infrastructure)
• Offset by opioid settlement payments ($6.4B over 18 years) and modest organic growth

source: coverage-next-full | ticker: CAH | step: "12" | created: 2026-05-29

Step 12 — Catalysts & Variant Analysis: Cardinal Health (CAH)

Near-Term Catalysts (0–12 Months)

1. Medical Segment Margin Progress

The most watched metric quarter-to-quarter. Any quarter where Medical adj. operating margin exceeds ~2.0–2.5% will re-rate the stock. Management's FY2025 guidance of ~$300–350M in Medical adj. OI (vs. ~$280M in FY2024) implies ~7–25% growth. Upside to these targets would be a positive catalyst.

2. FY2025 Guidance Update / Beat

With non-GAAP adj. EPS guidance of ~$8.00–8.50 for FY2025, any upward revision (driven by specialty volume, Medical recovery, or buybacks) would push consensus higher and likely re-rate the stock. Q3 FY2025 earnings (reported ~May 2025) and Q4 FY2025 (reported ~August 2025) are the key reporting events.

3. Nuclear Pharmacy Strategic Announcement

The market has been waiting for clarity on the nuclear pharmacy business. Options discussed include:

• Standalone spinoff (could unlock $6–9B in value by applying a specialty healthcare multiple)
• JV or partnership with a radiopharmaceutical manufacturer
• Continued operation within CAH with improved disclosure Any announcement providing clarity would be a near-term positive catalyst.

4. CVS Contract Renewal

The CVS distribution agreement is periodically renewed. A successful multi-year renewal (reported publicly or implied by stable revenue guidance) removes a significant overhang and is modestly positive. Red Oak JV renewal (tied to distribution) would be similarly positive.

5. GLP-1 Volume Acceleration

If GLP-1 prescriptions (Ozempic, Wegovy, Mounjaro, Zepbound) continue to grow at 30–50%+ annually, CAH's Pharmaceutical segment revenue and fee income grow correspondingly. This is an ongoing structural tailwind — each quarter of strong GLP-1 data confirms the thesis.

Medium-Term Catalysts (12–36 Months)

6. New Radiopharmaceutical Product Launches

Multiple new radiopharmaceutical products are approaching commercialization:

• Alzheimer's amyloid/tau PET tracers: Growing diagnostic demand as anti-amyloid therapies (Leqembi, Kisunla) expand — requires amyloid PET confirmation, distributed through nuclear pharmacies
• Next-generation PSMA therapies: Pipeline drugs beyond Pluvicto from Novartis and others
• Actinium-based therapies: Higher potency, potentially larger market than lutetium therapies
• RYZ101, iQS-001, and other pipeline agents: ~10–15 new radiopharmaceutical approvals expected 2025–2028

CAH's nuclear pharmacy network is the natural distribution partner for all these launches.

7. Share Count Reduction Compounding

At the current pace (~$2B+ in buybacks/year vs. ~$28B market cap), CAH retires ~7–8% of shares annually. Over 3 years, this represents ~20% fewer shares outstanding, driving ~25% adj. EPS growth even if operating earnings hold flat. This mechanical EPS growth provides a durable return in a low-growth environment.

8. M&A in Nuclear or Specialty

An accretive acquisition in the nuclear pharmacy or specialty distribution space could accelerate growth. Potential targets: radiopharmaceutical logistics specialists, specialty distribution bolt-ons, or nuclear pharmacy networks outside the US.

Structural Thesis: GLP-1 + Specialty + Nuclear as Three-Layer Growth

The most compelling medium-term thesis is that CAH has three simultaneously accelerating growth drivers that the market is not fully pricing in:

1. GLP-1 volumes (100M+ potential patients; ~$150–200B eventual market)
2. Specialty pharmaceutical growth (10–15%/year sector growth)
3. Nuclear pharmacy expansion (theranostic medicine secular growth)

All three benefit Cardinal Health disproportionately relative to its historical baseline.

Bull Case

• GLP-1 drug distribution volumes continue growing at 25–40% annually, adding ~$0.50–1.00/share to annual adj. EPS over 3 years through volume-driven fee income expansion
• Medical segment achieves 3–4% operating margins by FY2027, adding ~$300–400M in adj. OI vs. current run rate, representing ~$1.00–1.30/share additional EPS
• Nuclear pharmacy is spun off or sold at specialty healthcare multiples (15–20x EBITDA), unlocking $6–9B in value ($25–38/share) that is currently embedded in the stock at distribution multiples

Bear Case

• CVS Health terminates or substantially renegotiates its distribution agreement at contract renewal, reducing Pharmaceutical segment revenue by 20–25% and adj. OI by 30–35%, creating a structural earnings reset and potentially 40–50% stock price decline
• Drug pricing reform expands significantly beyond the IRA's initial scope — Congress enacts mandatory rebate elimination or price caps that restructure distributor economics, compressing fee income by 2–3% on branded drugs and reducing adj. EPS by 15–25%
• Medical segment turnaround stalls at ~1.5–2.0% operating margins due to ongoing GPO pricing pressure and manufacturing cost inflation, eroding management credibility and removing the key near-term earnings growth driver, leading to multiple compression to 11–12x forward adj. EPS